Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.

Christina Gewinner, Zhigang C. Wang, Andrea Richardson, Julie Teruya-Feldstein, Dariush Etemadmoghadam, David Bowtell, Jordi Barretina, William M. Lin, Lucia Rameh, Leonardo Salmena, Pier Paolo Pandolfi, Lewis C. Cantley, Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling Cancer Cell. ,vol. 16, pp. 115- 125 ,(2009) , 10.1016/J.CCR.2009.06.006

Ted S Gansler, William Hardman, Dirk A Hunt, Steven Schaffel, Randolph A Hennigar, Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival Human Pathology. ,vol. 28, pp. 686- 692 ,(1997) , 10.1016/S0046-8177(97)90177-5

F. Schmit, T. Utermark, S. Zhang, Q. Wang, T. Von, T. M. Roberts, J. J. Zhao, PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context Proceedings of the National Academy of Sciences of the United States of America. ,vol. 111, pp. 6395- 6400 ,(2014) , 10.1073/PNAS.1323004111

John D. Carpten, Andrew L. Faber, Candice Horn, Gregory P. Donoho, Stephen L. Briggs, Christiane M. Robbins, Galen Hostetter, Sophie Boguslawski, Tracy Y. Moses, Stephanie Savage, Mark Uhlik, Aimin Lin, Jian Du, Yue-Wei Qian, Douglas J. Zeckner, Greg Tucker-Kellogg, Jeffrey Touchman, Ketan Patel, Spyro Mousses, Michael Bittner, Richard Schevitz, Mei-Huei T. Lai, Kerry L. Blanchard, James E. Thomas, A transforming mutation in the pleckstrin homology domain of AKT1 in cancer Nature. ,vol. 448, pp. 439- 444 ,(2007) , 10.1038/NATURE05933

M Crul, H Rosing, G.J de Klerk, R Dubbelman, M Traiser, S Reichert, N.G Knebel, J.H.M Schellens, J.H Beijnen, W.W ten Bokkel Huinink, Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours European Journal of Cancer. ,vol. 38, pp. 1615- 1621 ,(2002) , 10.1016/S0959-8049(02)00127-2

Alexander P. Sobinoff, Brett Nixon, Shaun D. Roman, Eileen A. McLaughlin, Staying alive: PI3K pathway promotes primordial follicle activation and survival in response to 3MC-induced ovotoxicity. Toxicological Sciences. ,vol. 128, pp. 258- 271 ,(2012) , 10.1093/TOXSCI/KFS137

Dos D Sarbassov, David A Guertin, Siraj M Ali, David M Sabatini, Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science. ,vol. 307, pp. 1098- 1101 ,(2006) , 10.1126/SCIENCE.1106148

Koji Ichikawa, Tetsuya Abe, Hideki Nagase, Hitoshi Saito, Ryouto Fujita, Megumu Okada, Kazuhiko Yonekura, Toshiyasu Shimomura, Teruhiro Utsugi, Abstract C177: TAS-117, a highly selective non-ATP competitive inhibitor of AKT demonstrated antitumor activity in combination with chemotherapeutic agents and molecular targeted drugs. Molecular Cancer Therapeutics. ,vol. 12, ,(2013) , 10.1158/1535-7163.TARG-13-C177

X Wan, B Harkavy, N Shen, P Grohar, L J Helman, Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. ,vol. 26, pp. 1932- 1940 ,(2007) , 10.1038/SJ.ONC.1209990

Sarah Blagden, Aurelius Olmin, Debra Josephs, Chara Stavraka, Andrea Zivi, David J. Pinato, Alan Anthoney, Shaun Decordova, Karen Swales, Ruth Riisnaes, Lorna Pope, Kohei Noguchi, Rie Shiokawa, Michiyasu Inatani, Jenny Prince, Keith Jones, Chris Twelves, James Spicer, Udai Banerji, First-in-Human study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics and Pharmacodynamics, in Patients with Metastatic Cancer Clinical Cancer Research. ,vol. 20, pp. 5908- 5917 ,(2014) , 10.1158/1078-0432.CCR-14-1315